SCHEMBL16111153

SCHEMBL16111153

c1cc(N2CCN(C3COC3)CC2)c2ccncc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.44
P2RX7 Q99572 2/20 0.43
HRH3 Q9Y5N1 1/20 0.42
CYP11B1 P15538 3/20 0.41
CYP11B2 P19099 3/20 0.41
TRPV1 Q8NER1 1/20 0.40
F2 P00734 1/20 0.39
F12 P00748 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
DRD2 P14416 3/20 0.38
DRD3 P35462 3/20 0.38
CHRM1 P11229 1/20 0.38
HTR1A P08908 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15488697 0.80 POLB (0.52) PHGDHP2RX7CYP11B1CYP11B2TRPV1
SCHEMBL14860965 0.80 HRH3 (0.61) PHGDHP2RX7HRH3CYP11B1CYP11B2
SCHEMBL14861127 0.77 LATS1 (0.52) PHGDHP2RX7LMNACYP1A2CYP3A4
SCHEMBL16041849 0.75 ATR (0.44) F2F12ATR
SCHEMBL15770689 0.75 MAPT (0.51) F2F12ATR
SCHEMBL2420958 0.75 CYP2D6 (0.66) PHGDHLMNACYP1A2CYP3A4CYP2D6
SCHEMBL16111150 0.72 PHGDH (0.45) PHGDHP2RX7HRH3LMNACYP1A2
SCHEMBL17729077 0.72 ALDH1A1 (0.52) PHGDHP2RX7LMNACYP1A2CYP3A4
SCHEMBL17737440 0.72 P2RX7 (0.56) PHGDHP2RX7CYP11B1CYP11B2TRPV1
SCHEMBL16437213 0.72 TRPV6 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978751-B1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-12-05 EP disclosed
US-9738655-B2 Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-22 US disclosed
US-20160145263-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-05-26 US disclosed
EP-2978751-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2016-02-03 EP disclosed
WO-2014160668-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145263-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS TFPI2, TFPI, F12 PHGDH 3631/4885P2RX7 1953/4885HRH3 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.